Balchem Corporation BCPC

Company Overview

Balchem Corporation is a U.S.-based specialty ingredients and nutrition company that develops, manufactures, and markets performance ingredients and products for the food, nutrition, pharmaceutical, medical device, and animal health industries. The company operates primarily in specialty chemicals and human and animal nutrition markets, with a focus on microencapsulation technology, mineral nutrients, choline production, and functional ingredients. Balchem’s business model centers on supplying scientifically formulated ingredients that improve health, stability, safety, and performance across industrial and consumer applications.

The company’s primary revenue drivers include its Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products segments. Balchem serves food and beverage manufacturers, dietary supplement producers, pharmaceutical companies, livestock feed producers, and industrial customers globally. A distinguishing aspect of the company is its proprietary encapsulation and nutrient-delivery technologies, which support product stability, controlled release, taste masking, and enhanced nutrient absorption. Founded in 1967, Balchem initially focused on specialty chemicals before expanding through acquisitions and internal development into nutrition and health-focused markets, including significant growth in nutraceuticals and choline-based products.

Business Operations

Balchem organizes its operations into three primary reporting segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products. The Human Nutrition & Health segment produces functional ingredients, encapsulated nutrients, minerals, and food ingredients used in dietary supplements, beverages, clinical nutrition, infant nutrition, and pharmaceuticals. The Animal Nutrition & Health segment focuses on nutrient products for dairy, beef, poultry, and companion animals, particularly rumen-protected nutrients and choline products. The Specialty Products segment includes encapsulated and industrial-grade chemicals used in sterilization, fumigation, and plant nutrition applications.

The company maintains manufacturing, research, and distribution operations in the United States and internationally, supporting customers across North America, Europe, Asia, Latin America, and other global markets. Balchem controls proprietary technologies related to encapsulation and nutrient delivery systems, which are central to its competitive positioning. Important subsidiaries and acquired businesses include SensoryEffects, Albion International, Bergstrom Nutrition, and Kappa Bioscience, which expanded Balchem’s capabilities in mineral amino acid chelates, nutraceutical ingredients, flavor systems, and vitamin K2 technologies. Revenue is generated primarily through long-term customer relationships, specialty ingredient sales, and value-added nutritional solutions.

Strategic Position & Investments

Balchem’s strategic direction has focused on expanding its position in health and wellness, specialty nutrition, and scientifically differentiated ingredient technologies. The company has invested in higher-margin human nutrition products, clinically supported nutraceutical ingredients, and global expansion of its specialty nutrition platforms. Acquisitions have played a major role in this strategy, particularly the purchases of Albion International, Bergstrom Nutrition, and Kappa Bioscience, which strengthened Balchem’s portfolio in chelated minerals, methylsulfonylmethane (MSM), and vitamin K2 ingredients, respectively.

The company continues to emphasize innovation in microencapsulation, mineral delivery technologies, and precision nutrition. Balchem has also invested in manufacturing capacity expansion and research capabilities to support growing demand for health-oriented consumer products and specialty animal nutrition. Its strategy reflects broader industry trends toward preventive health, clean-label ingredients, clinical nutrition, and productivity-enhancing animal feed solutions. Public disclosures and investor communications consistently identify science-backed formulations, regulatory expertise, and specialized production capabilities as core strategic advantages.

Geographic Footprint

Balchem is headquartered in Montvale, New Jersey, and operates manufacturing, technical, and commercial facilities across multiple global regions. The company maintains a significant presence in the United States while also operating throughout Europe, Asia-Pacific, and Latin America. Its international footprint supports multinational food, pharmaceutical, and animal nutrition customers through regional manufacturing and distribution networks.

The company’s acquisitions have expanded its operational influence internationally, particularly in Norway, where Kappa Bioscience strengthened Balchem’s European nutraceutical capabilities, and through broader ingredient distribution networks across global health and nutrition markets. Balchem’s products are sold in numerous countries, and its international operations support both direct sales and strategic commercial partnerships in nutrition and specialty ingredient sectors.

Leadership & Governance

Balchem is led by an executive team with backgrounds in specialty ingredients, nutrition science, manufacturing, and global operations. The company’s governance structure follows a publicly traded corporate framework consistent with U.S. listed companies, with oversight provided by a board of directors and executive leadership team. Management strategy has emphasized operational discipline, innovation, acquisition integration, and long-term growth in science-driven nutrition markets.

Key executives include:

• Theodore L. Harris – Chairman of the Board, President and Chief Executive Officer
• Martin Bengtsson – Chief Financial Officer
• Jonathan Griffin – Vice President, General Counsel and Corporate Secretary
• Todd Krueger – President, Human Nutrition & Health
• Jonathan Young – President, Animal Nutrition & Health
• Scott Kirsner – President, Specialty Products

Company leadership has consistently communicated a strategic vision centered on innovation, specialty nutrition expansion, operational efficiency, and disciplined capital allocation. Public filings and investor materials emphasize sustainable growth through differentiated ingredient technologies, customer-focused product development, and targeted acquisitions aligned with health and wellness trends.